Problem Diabetic nephropathy (T2DM)
Format -
Treatment Irbesartan
Control Placebo
Population 590
Inclusion criteria -
Exclusion criteria -
Follow-up 2 years
Primary endpoint Composite of doubling serum creatinine, end stage renal failure and mortality
Secondary endpoint(s) -
Details -
Brief summary:
PAPER: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
Date 20 Sep 2001
Journal N Engl J Med. 2001 Sep 20;345(12):870-8.
Information Irbesartan is renoprotective independently of its blood-pressure-lowering effect in patients with type 2 diabetes and microalbuminuria.
PAPER: Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
Date 1 Apr 2003
Journal Ann Intern Med. 2003 Apr 1;138(7):542-9.
Information Composite cardiovascular event rate did not differ in patients with type 2 diabetes and overt nephropathy treated with irbesartan, amlodipine, or placebo in addition to conventional antihypertensive therapy.